Lucid Diagnostics Inc. (LUCD)
NASDAQ:LUCD
LUCD Stock Chart & Stats
$1.22
>-$0.01(-1.09%)
At close: 4:00 PM EST
$1.22
>-$0.01(-1.09%)
Day’s Range― - ―
52-Week Range$0.95 - $1.80
Previous CloseN/A
Volume130.18K
Average Volume (3M)1.93M
Market Cap
$198.18M
Enterprise Value-$8.77B
Total Cash (Recent Filing)$34.70B
Total Debt (Recent Filing)$25.82B
Price to Earnings (P/E)―
Beta0.18
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding176,945,970
10 Day Avg. Volume658,155
30 Day Avg. Volume1,931,035
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.01
Price to Sales (P/S)0.02
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-44.25
Enterprise Value/Revenue-1.86
Enterprise Value/Gross Profit4.46
Enterprise Value/Ebitda155.97
Forecast
1Y Price Target
$3.00Price Target Upside145.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Adoption And Sales ProductivityIncreased physician adoption of the EsoGuard test combined with improved sales team productivity drove higher-than-expected revenue and testing volume, signaling strengthening market demand.
Government Contract ExpansionAward of a Department of Veterans Affairs contract expands access to the esophageal test across a large integrated healthcare system and could materially increase the addressable market and revenue.
Reimbursement And Medicare ProgressAdvancement toward Medicare coverage following a favorable Contractor Advisory Committee outcome and progress on commercial payor strategies raises the likelihood of broader insurance coverage, supporting wider test adoption and revenue growth.
Bears Say
Cash Position And Capital NeedsCurrent cash levels combined with ongoing operating losses indicate the company will likely need to raise additional capital to fund operations and commercialization efforts, creating potential dilution risk.
Rising Operating ExpensesOperating expenses exceeding analyst estimates and increased cash burn pressure available resources and may limit near-term profitability until revenue scales further.
Lucid Diagnostics News
LUCD FAQ
What was Lucid Diagnostics Inc.’s price range in the past 12 months?
Lucid Diagnostics Inc. lowest stock price was $0.95 and its highest was $1.80 in the past 12 months.
What is Lucid Diagnostics Inc.’s market cap?
Lucid Diagnostics Inc.’s market cap is $198.18M.
When is Lucid Diagnostics Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Lucid Diagnostics Inc.’s earnings last quarter?
Currently, no data Available
Is Lucid Diagnostics Inc. overvalued?
According to Wall Street analysts Lucid Diagnostics Inc.’s price is currently Undervalued.
Does Lucid Diagnostics Inc. pay dividends?
Lucid Diagnostics Inc. does not currently pay dividends.
What is Lucid Diagnostics Inc.’s EPS estimate?
Lucid Diagnostics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lucid Diagnostics Inc. have?
Lucid Diagnostics Inc. has 176,945,970 shares outstanding.
What happened to Lucid Diagnostics Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lucid Diagnostics Inc.?
Currently, no hedge funds are holding shares in LUCD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lucid Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.00 (145.90% Upside)
$3.00 (145.90% Upside)
Blogger Sentiment
Bullish
LUCD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 29.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bullish
Bullish news 86%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.03%
12-Months-Change
Fundamentals
Return on Equity
-9999.00%
Trailing 12-Months
Asset Growth
31.68%
Trailing 12-Months
Company Description
Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
LUCD Company Deck
LUCD Earnings Call
Q4 2026
0:00 / 0:00
LUCD Stock 12 Month Forecast
Average Price Target
$3.00
▲(145.90% Upside)
Technical Analysis
Ownership Overview
8.12% Insiders
4.69% Mutual Funds
7.16% Other Institutional Investors
73.89% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---